Single-fraction preoperative ablative stereotactic partial breast irradiation (sPBI) can be safely delivered in early-stage hormone receptor–positive (HR+) breast cancer with delayed time to surgery and high pathologic complete response rates. This evidence concerns the gene NR4A1 and breast carcinoma.